– IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 – – Established new strategic collaboration with Celest Therapeutics for ...

Find the latest historical data for Senti Biosciences, Inc. Common Stock (SNTI) at Nasdaq.com. View historical data in a monthly, bi-annual, or yearly format.

A high-level overview of Senti Biosciences, Inc. (SNTI) stock. View (SNTI) real-time stock price, chart, news, analysis, analyst reviews and more.

Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro.

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene ...

SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next ...

Senti Biosciences Inc has a consensus price target of $9 based on the ratings of 5 analysts. The high is $15 issued by Laidlaw & Co. on June 6, 2025.The low is $2 issued by Morgan Stanley on March ...

Senti Biosciences will present its innovative tumor-specific therapy at the 2025 SEED Conference in Houston, Texas. ... This data feed is not available at this time.

SENTI-202 targets CD33 or FLT3, sparing EMCN, enhancing precision in treating hematologic malignancies like AML. Preliminary data shows high efficacy, with significant composite complete remission ...

SENTI-301A is an off-the-shelf CAR-natural killer cell therapy for GPC3 expressing tumors derived from healthy donor cells. The therapy was shown in preclinical testing to kill relevant tumor cells.